Long-Term Treatment Outcomes of Patients Infected With Hepatitis C Virus: A Systematic Review and Meta-analysis of the Survival Benefit of Achieving a Sustained Virological Response.
about
Management of HCV-Associated Liver Cirrhosis.Price and affordability of direct-acting antiviral regimens for hepatitis C virus in the United StatesRecent advances in managing chronic HCV infection: focus on therapy in patients with severe liver diseaseHepatitis C virus: A time for decisions. Who should be treated and when?Value of Treating All Stages of Chronic Hepatitis C: A Comprehensive Review of Clinical and Economic EvidenceRisk of Late Relapse or Reinfection With Hepatitis C Virus After Achieving a Sustained Virological Response: A Systematic Review and Meta-analysisReinventing HCV Treatment: Past and Future Perspectives.Stroke in HIV-infected individuals with and without HCV coinfection in Spain in the combination antiretroviral therapy era.Medical and Behavioral Approaches to Engage People Who Inject Drugs Into Care for Hepatitis C Virus Infection.Achieving Sustained Virological Response in Hepatitis C Reduces the Long-Term Risk of Hepatocellular Carcinoma: An Updated Meta-Analysis Employing Relative and Absolute Outcome Measures.The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013Twin epidemics of new and prevalent hepatitis C infections in Canada: BC Hepatitis Testers Cohort.A population-based study of chronic hepatitis C in immigrants and non-immigrants in Quebec, CanadaHighlights of the Fourth Canadian Symposium on Hepatitis C: Moving towards a National Action Plan.Management of Hepatitis C/HIV Coinfection in the Era of Highly Effective Hepatitis C Virus Direct-Acting Antiviral Therapy.A real-world intention-to-treat analysis of a decade's experience of treatment of hepatitis C with interferon-based therapies.The Population Level Cascade of Care for Hepatitis C in British Columbia, Canada: The BC Hepatitis Testers Cohort (BC-HTC)The HCV Treatment Revolution Continues: Resistance Considerations, Pangenotypic Efficacy, and Advances in Challenging Populations.Review article: treatment as prevention - targeting people who inject drugs as a pathway towards hepatitis C eradication.Hepatitis C virus treatment in the real world: optimising treatment and access to therapies.Non-healthcare costs of hepatitis C: A systematic review.Dual sofosbuvir and ribavirin therapy for chronic hepatitis C infection.Is the benefit of treating patients with cirrhosis proven?Follow-up of patients with chronic hepatitis C and a sustained viral response.Infectious Considerations in the Pre-Transplant Evaluation of Cirrhotic Patients Awaiting Orthotopic Liver Transplantation.Advances in the management of HIV/HCV coinfection.Optimum combination therapy regimens for HIV/HCV infection.Buying cures versus renting health: Financing health care with consumer loans.High prevalence of willingness to use direct-acting antiviral-based regimens for hepatitis C virus (HCV) infection among HIV/HCV coinfected people who use drugs.Liver-related mortality and hospitalizations attributable to chronic hepatitis C virus coinfection in persons living with HIV.Effectiveness and safety of daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: Systematic review and meta-analysis.Evaluation of a Hepatitis C Patient Management Program at a University Specialty Pharmacy.The impact of hepatitis C virus outside the liver: Evidence from Asia.Eradication of hepatitis C virus and non-liver-related non-acquired immune deficiency syndrome-related events in human immunodeficiency virus/hepatitis C virus coinfection.Trends in HCV treatment uptake, efficacy and impact on liver fibrosis in the Swiss HIV Cohort Study.Progress in eradication of HCV in HIV positive patients with significant liver fibrosis in Vienna.Characterization of chronic HCV infection in Northwest Spain: Impact of the treatment strategic plan of the Spanish National Health Service on HCV cure.Interferon-free regimens improve portal hypertension and histological necroinflammation in HIV/HCV patients with advanced liver disease.Fibrosis Progression in Patients With Chronic Hepatitis C Virus Infection.Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network.
P2860
Q26740320-33FB125A-405B-4767-B87C-B29D76274BF3Q26749246-35E663D3-D420-4E9E-B484-32C2EAFAE861Q26752433-E0595352-66EB-4B0C-8F51-59E1D5F23C82Q26768274-CEFC5D69-8592-435C-8C30-104BF782B812Q28072257-D8C42E96-729D-45A9-B122-4359F25C87DAQ28076352-AB407D72-C7FB-47E7-89BA-D66843D17EB2Q30241881-5AE7D8B4-DED5-490B-98F0-B6FDE50A3720Q33803319-462AE65D-CB6E-415F-9F22-8ACAFE597ACBQ33853664-EF731E7E-ACF1-4087-8077-C9D49A8750D9Q34497272-B3DDC956-3A94-4556-B0EA-1D3FE572191CQ34533596-F01018BE-4E12-4D56-B894-9EB4BB72A582Q36082433-C711B013-EC31-4A11-94CB-872E31BAE251Q36279118-85C5CDC3-C704-41E6-B0E0-C25A64599AAEQ36997093-53539CE2-DCA8-475E-A566-B93DD63E1E49Q37055228-D14D303F-6EB5-472E-B591-2BC5896FDA9AQ37279260-F27951E4-32F5-449E-913A-EC55F6C6D365Q37363491-61E9CFC1-B4EF-4506-BEDE-3B1F388CE66AQ37555313-D6409C85-2256-47EC-B7A2-AF9B97192162Q38380343-FB801492-35D7-4E73-88DA-01FA0063B966Q38602682-A9216882-4E1F-4724-985C-1E798FEF11D9Q38606907-9CC96EAB-5F7A-4568-AB13-D10FEED15348Q38630475-B9810255-A0C9-49F4-8052-DE3CC96BF05CQ38685569-1AEF0221-95DF-40E9-8E88-C132FBB36DEBQ38685584-9B9FC90A-AF52-4B60-B98F-C1680DCEE451Q38689820-A633E120-B53B-44DC-8A39-59166F68FC25Q38693820-21CCCF64-669A-41BD-8DD0-39B3CCA128B7Q38715477-0726CB41-9A85-41C0-BD5F-900A6C69A4E9Q38749220-1AB3C8E0-0120-4F0C-82B0-5EDF3048EB22Q38907436-2255C107-BF3E-43C2-891D-CBFFC10C6C98Q38946506-A6A15954-6132-4488-9C7D-9E55FDF881E6Q38946893-0F64BF3E-34DD-4FC4-8361-1C683D01F290Q38947814-8327A6D3-2A2E-47F9-AFF7-F52F5E6C5AB5Q38982462-F25290F3-634E-46B5-8C47-B65B12A66CFEQ39008634-623D4A79-6B20-4371-A634-BFF9F4B5553DQ40109414-67D864BA-F459-4765-ABEF-5A006E39D2A3Q40355278-B8125FD2-968B-441D-82EB-47C25938B162Q40375159-A37B2822-8FE6-42C1-A398-14B736A0F026Q40426656-F5FDFF89-912C-4BD9-9406-5A670633C805Q40590610-ADF77BD2-F718-4D1D-91EA-E1B9BCBC9A88Q41924669-B40619FA-C660-4ABA-954F-9709A6F40669
P2860
Long-Term Treatment Outcomes of Patients Infected With Hepatitis C Virus: A Systematic Review and Meta-analysis of the Survival Benefit of Achieving a Sustained Virological Response.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Long-Term Treatment Outcomes o ...... ustained Virological Response.
@ast
Long-Term Treatment Outcomes o ...... ustained Virological Response.
@en
type
label
Long-Term Treatment Outcomes o ...... ustained Virological Response.
@ast
Long-Term Treatment Outcomes o ...... ustained Virological Response.
@en
prefLabel
Long-Term Treatment Outcomes o ...... ustained Virological Response.
@ast
Long-Term Treatment Outcomes o ...... ustained Virological Response.
@en
P2093
P2860
P31
P356
P1476
Long-Term Treatment Outcomes o ...... ustained Virological Response.
@en
P2093
Andrew Hill
Graham S Cooke
Jawaad Saleem
P2860
P304
P356
10.1093/CID/CIV396
P407
P577
2015-05-17T00:00:00Z
2015-09-01T00:00:00Z